Phase 1 study for ONO-3951

Phase 1 study for ONO-3951 Effect of age and gender on pharmacokinetics of ONO-3951

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221431

Enrollment

Registered

2011-04-15

Start date

2011-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

investigational material(s) Generic name etc : ONO-3951 INN of investigational material : asimadoline Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Healthy male and female volunteers 2.Age Group1:20-40 years, Group2:41-64 years, Group3: 65-74 years

Exclusion criteria

Exclusion criteria: Subjects with therapy for the diseases of Respiratory system, Cardiovascular system, Central nervous system, Digestive system, Liver, Kidney, Hematopoietic system and Endocrine system within past 3 months.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic, Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026